Rare Genetic Disorder Yields to Targeted Hormone Receptor Antagonist
Environmental Science

Rare Genetic Disorder Yields to Targeted Hormone Receptor Antagonist

A 23-year-old woman with severe, treatment-resistant hypertension found relief through a newly approved therapy.

By Raj Joshi
Published:
Email this Article
Rare Genetic Disorder Yields to Targeted Hormone Receptor Antagonist
Photo by digitale.de on Unsplash

A 23-year-old woman suffering from a rare genetic condition experienced a dramatic drop in dangerously high blood pressure after doctors administered an experimental medication usually reserved for a more common form of the disease. The patient lived with a severe, treatment-resistant form of congenital adrenal hyperplasia, which is a group of inherited disorders affecting hormone production in the adrenal glands.

Her condition was specifically caused by a deficiency in an enzyme known as 17-alpha-hydroxylase and 17,20-lyase, accounting for roughly one percent of all congenital adrenal hyperplasia cases. This rare enzymatic block triggers an overproduction of a powerful hormone called deoxycorticosterone, which acts as a mineralocorticoid and drives severe, low-renin hypertension along with low blood potassium levels. Despite taking high doses of multiple blood pressure medications, including 600 milligrams of spironolactone daily, her blood pressure remained persistently uncontrolled at readings above 150 over 120 millimeters of mercury.

To investigate a new therapeutic avenue, the medical team published in JCEM Case Reports detailing the unprecedented intervention. The researchers turned to crinecerfont, a selective corticotropin-releasing factor type 1 receptor antagonist that received U.S. Food and Drug Administration approval in 2024 for classic congenital adrenal hyperplasia. While previous clinical trials focused almost exclusively on the more common 21-hydroxylase deficiency, the drug’s mechanism of blocking pituitary adrenocorticotropic hormone secretion offered a theoretical way to halt the overproduction of adrenal steroid precursors.

Figure 1: Pathophysiology of CAH due to 17α-hydroxylase deficiency (17OHD). The enzymatic defect results in increased mineralocorticoid precursor production and reduced cortisol and androgen synthesis. Decreased cortisol secretion leads to increased ACTH production through loss of negative feedback on the hypothalamic-pituitary-adrenal axis. Crinecerfont, a CRF1 receptor antagonist, suppresses ACTH secretion, thereby reducing excess mineralocorticoid precursor production. Figure created with BioRender.com and adapted by the authors. ACTH, Adrenocorticotropic hormone; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; CRF1, corticotropin-releasing factor 1; 17-OHP, 17-hydroxyprogesterone.
Pathophysiology of CAH due to 17α-hydroxylase deficiency (17OHD). The enzymatic defect results in increased mineralocorticoid precursor production and reduced cortisol and androgen synthesis. Decreased cortisol secretion leads to increased ACTH production through loss of negative feedback on the hypothalamic-pituitary-adrenal axis. Crinecerfont, a CRF1 receptor antagonist, suppresses ACTH secretion, thereby reducing excess mineralocorticoid precursor production. Figure created with BioRender.com and adapted by the authors. ACTH, Adrenocorticotropic hormone; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; CRF1, corticotropin-releasing factor 1; 17-OHP, 17-hydroxyprogesterone. Credit: Azucena Herrera Chancay et al. / JCEM case reports

How the Novel Drug Restored Hormonal Balance

Before starting the new therapy, the patient required aggressive pharmaceutical regimens that failed to bring her hormone levels into a safe range. Her deoxycorticosterone and pregnenolone concentrations remained exceptionally high, fueling her treatment-resistant hypertension and contributing to significant weight gain. The medical team initiated crinecerfont at a dosage of 100 milligrams twice daily while keeping her glucocorticoid regimen stable.

Following the introduction of the receptor antagonist, the patient experienced a rapid and substantial improvement in both clinical and biochemical markers. Her blood pressure dropped to a much safer range of 120 to 130 over 80 to 90 millimeters of mercury without requiring any further escalation of her antihypertensive medications. Furthermore, her plasma renin activity normalized to 7.4 nanograms per milliliter per hour, and both deoxycorticosterone and pregnenolone concentrations dropped back into normal ranges.

What This Means for Future Rare Disease Treatments

The successful outcome persisted throughout a 12-month follow-up period, demonstrating sustained disease control. During this time, the patient also experienced a reduction in body mass index down to 29 kilograms per meter squared, aided by concurrent weight management therapies. The clinical findings suggest that targeting corticotropin-releasing factor receptors can effectively manage forms of adrenal hyperplasia driven by excess mineralocorticoids that do not respond to conventional care.

Figure 2: Changes in antihypertensive medication regimen before and after initiation of crinecerfont. Longitudinal timeline of antihypertensive medication use during the 23 months preceding and 10 months following crinecerfont initiation (month 0). Colored symbols indicate individual antihypertensive agents, with the dose shown within each symbol. Prior to crinecerfont treatment, progressive intensification of antihypertensive therapy was required, including dose escalation and addition of multiple agents. Following crinecerfont initiation, the antihypertensive regimen remained stable without further escalation. Colors indicate individual medications as shown in the legend. Dose levels are shown relative to commonly prescribed dose ranges: spironolactone (12.5-100 mg/day), valsartan (80-320 mg/day), carvedilol (6.25-50 mg/day), metoprolol succinate (25-200 mg/day), hydrochlorothiazide (12.5-50 mg/day), and amlodipine besylate (2.5-10 mg/day). An upward slope indicates a dose increase.
Changes in antihypertensive medication regimen before and after initiation of crinecerfont. Longitudinal timeline of antihypertensive medication use during the 23 months preceding and 10 months following crinecerfont initiation (month 0). Colored symbols indicate individual antihypertensive agents, with the dose shown within each symbol. Prior to crinecerfont treatment, progressive intensification of antihypertensive therapy was required, including dose escalation and addition of multiple agents. Following crinecerfont initiation, the antihypertensive regimen remained stable without further escalation. Colors indicate individual medications as shown in the legend. Dose levels are shown relative to commonly prescribed dose ranges: spironolactone (12.5-100 mg/day), valsartan (80-320 mg/day), carvedilol (6.25-50 mg/day), metoprolol succinate (25-200 mg/day), hydrochlorothiazide (12.5-50 mg/day), and amlodipine besylate (2.5-10 mg/day). An upward slope indicates a dose increase. Credit: Azucena Herrera Chancay et al. / JCEM case reports

The authors noted that ordinary clinical indicators can sometimes be misleading in these rare cases. Throughout the patient’s care, her adrenocorticotropic hormone levels were only mildly elevated or remained within normal limits despite severe underlying disease activity and soaring precursor hormones. This discordance highlights the importance of monitoring specific steroid precursors and blood pressure trends rather than relying solely on standard hormone measurements.

While this single case provides promising evidence, the researchers emphasize that further investigation is necessary to understand the broader utility of corticotropin-releasing factor antagonists in rare adrenal subtypes. For patients who face severe cardiometabolic risks from high-dose steroid treatments and uncontrollable hypertension, this novel therapeutic approach offers a promising path forward.

The research was published in JCEM case reports on November 17, 2026.

Fact Checked

This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.

Last reviewed on .

Article history

  • Latest version

Reference(s)

  1. Herrera Chancay, Azucena., et al. “Successful hypertension control in 17-hydroxylase deficiency using crinecerfont.” JCEM Case Reports, vol. 4, no. 12, November 17, 2026 The Endocrine Society, doi: 10.1210/jcemcr/luag360. <https://doi.org/10.1210/jcemcr/luag360>.

Cite this page:

Joshi, Raj. “Rare Genetic Disorder Yields to Targeted Hormone Receptor Antagonist.” BioScience. BioScience ISSN 2521-5760, 20 November 2026. <https://www.bioscience.com.pk/en/subject/environmental-science/successful-hypertension-control-in-17-hydroxylase-deficiency-using-crinecerfont>. Joshi, R. (2026, November 20). “Rare Genetic Disorder Yields to Targeted Hormone Receptor Antagonist.” BioScience. ISSN 2521-5760. Retrieved November 20, 2026 from https://www.bioscience.com.pk/en/subject/environmental-science/successful-hypertension-control-in-17-hydroxylase-deficiency-using-crinecerfont Joshi, Raj. “Rare Genetic Disorder Yields to Targeted Hormone Receptor Antagonist.” BioScience. ISSN 2521-5760. https://www.bioscience.com.pk/en/subject/environmental-science/successful-hypertension-control-in-17-hydroxylase-deficiency-using-crinecerfont (accessed November 20, 2026).
  • Posted by
End of the article